BJDX - Bluejay Diagnostics Price to Earnings Adjusted for Growth Rate

The fabless production model for rapid tests optimizes costs for Bluejay Diagnostics (BJDX) by outsourcing assembly to external plants. The normalized PEG ratio visualizes the market response, where 0.00 shows the current value of the metric. Stable revenue is driven by the regular sale of sepsis diagnostic cartridges, while stringent FDA requirements and patents create an insurmountable barrier to entry for potential competitors.

Bluejay (BJDX): PEG Multiple from 07/04/2022 to 11/10/2026

Analytical breakdowns for Bluejay Diagnostics (BJDX)

- current price and projected stock value:

Price Chart Bluejay Diagnostics Inc|BJDX - Consensus Target

- market capitalization statistics:

Market Value Bluejay|BJDX - Total Company Value

- shareholders' equity book value data:

Net Assets per Share Bluejay Diagnostics|BJDX - Book Capitalization|Market Capitalization to Book Value bluejaydx.com|BJDX - Aggregate Company Assets

- issuer credit burden and liquidity indicators:

- net income and valuation ratios data:

BJDX - Company Net Income|Future Net Profit Bluejay Diagnostics|BJDX - P/E Multiple|Forward P/E Multiple Bluejay Diagnostics Corp|BJDX - Price/Earnings to Growth Multiple|Company Value to EBITDA Bluejay|BJDX - Operating profit before deduction of amortization|Earnings per share for the trailing year Bluejay Diagnostics|BJDX - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last 12 months bluejaydx.com|BJDX - Earnings growth in current year|Consensus forecast of earnings per share growth for next year Bluejay Diagnostics

Fundamental company analysis:Bluejay Diagnostics Inc BJDX

The PEG ratio compares the P/E multiple with earnings growth rates, allowing for the determination of an asset's fair value and the identification of undervaluation when the value is below one. By analyzing the PEG level dynamics with a value of 0.00, investors assess the expansion potential of Bluejay Diagnostics (BJDX) in the rapid sepsis diagnostics segment via the Symphony platform for emergency medicine.

Who Bluejay Diagnostics competes with